Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orexia Therapeutics
London, United Kingdomorexiatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Orexia developed oral and intranasal OX2R agonists using structure-based design. Its main asset, now advanced by Centessa Pharmaceuticals as ORX142, is in Phase 2, focusing on disorders related to orexin neuron loss such as narcolepsy type 1. First clinical trials in acutely sleep-deprived healthy volunteers planned for 2025[1][3][4].
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Sosei HeptaresMedicxiX-Chem
Beyond the preview
Go deeper on Orexia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orexia Therapeutics.